Semaglutide-Based Implant Agreement for Obesity Treatment from Vivani Medical and Novo Nordisk

Vivani Medical, an America Birleşik Devletleri-based biopharmaceutical company, has signed a significant agreement with the Danish giant Novo Nordisk to evaluate its next-generation implant named NPM-139, developed for the treatment of obesity. NPM-139 stands out as an ultra-long-acting mini implant manufactured using vivani's proprietary NanoPortal™ technology and containing the active ingredient semaglutide. This new generation medical device aims to allow patients to receive uninterrupted treatment for months by having the application done only once or twice a year. There is no exclusivity (private use) clause between the two parties within the scope of this agreement; therefore, Vivani's rights over the NanoPortal technology continue to be protected. This development shows that innovative steps are being taken to increase patient compliance in the treatment of obesity and metabolic diseases.

Dr. Adam Mendelsohn, Chief Executive Officer (CEO) of Vivani Medical, stated in his remarks regarding the matter that this agreement confirms the commercial potential of semaglutide-based implant programs. Mendelsohn emphasized that the current GLP-1-based implant development programs are promising enough to meet increasing patient demands. It was pointed out that serious problems, such as patients forgetting or neglecting to take daily or weekly medication in traditional treatment methods, are encountered. The company aims to provide psychological comfort by offering patients the flexibility to stop the treatment whenever they want with its new implant. It is stated that this method, which will be applied only once or twice a year, has the nature of a revolution that could completely change medication usage habits.

According to the roadmap announced by the company, Phase I clinical studies of the NPM-139 implant will be initiated in the middle of 2026. In this randomized study, the safety, pharmacokinetics, and patient tolerance of the implant developed by Vivani will be examined in detail. Furthermore, within the scope of the study, the currently popular obesity drug Wegovy® injectable solution will be used as an active comparator (control). In accordance with the data to be obtained from the Phase I studies and provided positive results are achieved, Phase II studies will be initiated to determine the optimum dose. This systematic research process has been designed to ensure that the implant meets all the necessary criteria for both scientific and legal approvals.

The NanoPortal™ platform, which forms the core of Vivani Medical, was designed to enable drug molecules to be released steadily and in a controlled manner over long periods in the human body. Thanks to this innovative technology, GLP-1-based drugs used in the treatment of metabolic diseases can be offered to patients in a form that can replace orally taken pills or frequently administered injections. It is planned to minimize problems such as the loss of efficacy and the increase in side effects experienced as a result of medication interruptions seen in traditional treatments, thanks to this implant. The problem known in the medical literature as "treatment non-compliance" or "non-observance," which involves the irregular use of prescription drugs at a rate of approximately fifty percent, can be largely solved with such long-acting implants. The company continues to invest heavily in this technology, especially for chronic conditions such as obesity and type 2 diabetes that affect millions of people worldwide.

This partnership news reveals that competition in the global obesity and weight management market is not limited only to drug formulations, but is also heating up in drug delivery technologies. The fact that a giant drug manufacturer like Novo Nordisk wants to evaluate Vivani's implant technology proves how important strategic partnerships are in the sector. The active ingredient semaglutide has currently gained massive popularity worldwide and has started to be used in many different treatment areas. However, annual implants that could replace daily or weekly injections have the potential to radically change market dynamics by incredibly increasing patient comfort. Provided the clinical trials are successful, it is seen as a strong possibility that such implant technologies will become one of the standard obesity treatments in the near future.